Identification of Different miRNAs and Their Relevant miRNA Targeted Genes Involved in Sister Chromatid Cohesion and Segregation (SCCS)/chromatin Remodeling Pathway on T1G3 Urothelial Carcinoma (UC) Response to BCG Immunotherapy.

Autor: Awadalla A; Center of Excellence for genome and cancer research, Urology and Nephrology Center, Mansoura University, Egypt., Zahran MH; Center of Excellence for genome and cancer research, Urology and Nephrology Center, Mansoura University, Egypt. Electronic address: zahranmha822@gmail.com., Abol-Enein H; Center of Excellence for genome and cancer research, Urology and Nephrology Center, Mansoura University, Egypt., Zekri AN; Cancer biology department, virology and immunology unit, National Cancer Institute, Cairo University., Elbaset MA; Center of Excellence for genome and cancer research, Urology and Nephrology Center, Mansoura University, Egypt., Ahmed AE; Center of Excellence for genome and cancer research, Urology and Nephrology Center, Mansoura University, Egypt., Hamam ET; Center of Excellence for genome and cancer research, Urology and Nephrology Center, Mansoura University, Egypt., Elsawy A; Center of Excellence for genome and cancer research, Urology and Nephrology Center, Mansoura University, Egypt., Khalifa MK; Omicsence, Cairo, Egypt., Shokeir AA; Center of Excellence for genome and cancer research, Urology and Nephrology Center, Mansoura University, Egypt.
Jazyk: angličtina
Zdroj: Clinical genitourinary cancer [Clin Genitourin Cancer] 2022 Jun; Vol. 20 (3), pp. e181-e189. Date of Electronic Publication: 2021 Dec 16.
DOI: 10.1016/j.clgc.2021.12.001
Abstrakt: Background: Till now, no definite clinical or laboratory marker can predict the recurrence or progression of T1 G3 urothelial carcinoma (UC). Genetic aberrations of the chromatin remodeling genes and sister chromatid cohesion and segregation (SCCS) were identified in UC. Here we investigated the impact of novel miRNAs and their targeted expressed SCCS and chromatin remodeling genes on T1G3 UC response to Bacillus Calmette-Guérin (BCG) therapy.
Methods: One hundred tissue samples were obtained from NMIBC patients. Gene expression and immunohistochemical assay of STAG2, ARID1A, NCOR1and UTX were assessed. MiRNA analysis for their targeting miRNAs (miR-21, miR-31, Let7a and miR-199a) was carried out. Assessed genes were compared between responders and no responders to BCG. Univariate and multivariate analysis of predictors of disease recurrence and progression were performed using cox regression analysis.
Results: Thirty-two and 22 patients developed recurrence and progression to MIBC (BCG non-responders). BCG non-responders showed statistically significant higher expression of miR-21 and their targeted STAG2, miR-199a and NCOR1 gene (P < .001), and lower expression of miR-31, Let7a, ARID1A and UTX genes (P < .001). Higher miR-199a (P = .006) and lower miR-31 (P = .01), ARID1A (P = .008) and UTX (P = .03) were independent predictor of higher tumor recurrence. Recurrent disease (P = .003), higher expression of STAG2 (P = .01), NCOR1 (P = .01) and miR-21 (P = .03) genes and lower expression of miR-31 (P = .02), Let7a (P = .04) and ARID1A (P = .04) genes were the independent predictor of disease progression.
Conclusion: Upregulation of STAG2 and NCOR1 and down regulation of ARID1A and UTX genes and their targeting miRNAs were associated with UC non-response to BCG.
(Copyright © 2021 Elsevier Ltd. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: